SCHEDULE: Squadron Entities Disclose Significant Traws Pharma Stake

Squadron Master Fund LP and related entities report beneficial ownership exceeding 5% in Traws Pharma, Inc. common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Traws Pharma, Inc.
• Squadron Master Fund LP beneficially owns 523,359 shares, representing 7.4% of Traws Pharma's common stock.
• Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank each beneficially own 591,000 shares, representing 8.4% of Traws Pharma's common stock.
• The ownership percentages are based on 7,063,829 shares of common stock outstanding as of August 12, 2025, as reported by Traws Pharma in its Form 10-Q filed on August 14, 2025.
• Squadron Capital Management LLC is an investment adviser, and Matthew Sesterhenn and William Blank are Partners of Squadron Capital Management, LLC, with shared voting and dispositive power over the reported shares.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Traws Pharma, Inc.

Sentiment

Score: 5

Explanation: Neutral filing reporting beneficial ownership changes, which is standard for Schedule 13G disclosures.

Positives

• The disclosure of significant institutional ownership by Squadron entities may signal confidence in Traws Pharma's long-term prospects.
• The filing indicates the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist stance.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant institutional investment in Traws Pharma, a company operating in the pharmaceutical sector. Such disclosures are common for publicly traded companies and reflect the ongoing investment activities of funds and their principals within the industry.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Company Management: Awareness of a significant shareholder group, though the filing indicates a passive investment intent.

Next Steps

• NA

Key Dates

Keywords

Traws Pharma, Squadron Master Fund, Squadron Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing